Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FERM domain-containing protein 3 (FRMD3) is a member of the FERM domain protein superfamily, characterized by a conserved ~150 amino acid FERM domain found in cytoskeletal adaptor proteins that link the cell membrane to the cytoskeleton[3][5]. FRMD3 acts as a tumor suppressor, notably in breast cancer, where it inhibits cell proliferation, migration, invasion, and metastasis, partly by promoting polyubiquitin-mediated degradation of vimentin and by regulating the Notch signaling pathway through destabilization of Disheveled-2 and modulation of epithelial cell fate[2][4]. FRMD3's low expression is associated with increased tumorigenic potential and poorer prognosis in breast cancer patients[4]. Its primary biological functions involve the maintenance of cytoskeletal architecture, control of cell morphology, and regulation of membrane-protein interactions[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FERM domain-containing protein 3 (FRMD3).